Iron Metabolism

Overview

Iron is an essential trace element required for oxygen transport (hemoglobin), electron transfer (cellular respiration), DNA synthesis, and enzymatic catalysis. The adult human body contains approximately 3-5 grams of iron, most of which (approximately 65%) is incorporated into hemoglobin in circulating red blood cells. The remainder is stored as ferritin (primarily in the liver), incorporated into myoglobin (muscle), or bound to iron-containing enzymes.

Iron metabolism is unique among mineral metabolisms because there is no regulated excretion pathway — iron losses occur only through cell shedding (skin, gut epithelium), menstruation, and minor bleeding. This means that iron homeostasis depends entirely on regulated absorption from the diet and recycling from senescent red blood cells. The master regulator of this system is hepcidin, a 25-amino-acid peptide hormone produced by the liver.

Hepcidin: The Iron-Regulatory Peptide

Hepcidin is the central regulatory peptide of iron metabolism. It is a small defensin-like peptide that acts by binding to ferroportin, the only known cellular iron exporter, causing its internalization and degradation. When hepcidin levels are high, ferroportin is removed from cell surfaces, trapping iron inside enterocytes (blocking absorption), macrophages (blocking recycling), and hepatocytes (blocking release from stores). When hepcidin is low, ferroportin is present on cell surfaces, and iron flows freely into the plasma.

Regulation of Hepcidin

Hepcidin expression is regulated by multiple signals:

• Iron status — High serum iron and transferrin saturation increase hepcidin via the BMP-SMAD signaling pathway, creating a negative feedback loop.
• Inflammation — IL-6 and other pro-inflammatory cytokines strongly induce hepcidin expression via the JAK-STAT pathway. This is the molecular basis of anemia of chronic disease (also called anemia of inflammation).
• Erythropoietic drive — Active erythropoiesis suppresses hepcidin through erythroferrone, a hormone released by erythroblasts, ensuring iron availability for hemoglobin synthesis.
• Hypoxia — Low oxygen levels suppress hepcidin, increasing iron availability for red blood cell production.

Iron Absorption

Dietary iron exists in two forms: heme iron (from animal sources, absorbed directly via the heme carrier protein HCP1) and non-heme iron (from plant sources, reduced from Fe3+ to Fe2+ by duodenal cytochrome b and absorbed via the divalent metal transporter DMT1). Heme iron is more efficiently absorbed (15-35%) than non-heme iron (2-20%).

Once inside the enterocyte, iron can be stored as ferritin or exported into the plasma via ferroportin, where it is oxidized to Fe3+ and loaded onto transferrin for transport. Hepcidin controls this export step, making it the gatekeeper of dietary iron absorption.

Iron Recycling

The largest source of iron for new hemoglobin synthesis is the recycling of iron from senescent red blood cells by macrophages of the reticuloendothelial system (primarily in the spleen). Macrophages phagocytose aged red blood cells, degrade hemoglobin, and release the iron back into the plasma via ferroportin. This recycling process provides approximately 20-25 mg of iron per day — far more than the 1-2 mg absorbed from the diet.

Clinical Relevance

Iron Deficiency Anemia

The most common nutritional deficiency worldwide. Causes include inadequate dietary intake, malabsorption (celiac disease, gastric bypass), chronic blood loss, and increased demand (pregnancy, growth). Iron deficiency impairs erythropoiesis, causing microcytic hypochromic anemia with symptoms of fatigue, weakness, and impaired exercise capacity.

Iron status is a standard component of blood work monitoring in peptide protocols, as many peptide users are also pursuing performance optimization where iron adequacy is essential.

Anemia of Chronic Disease

Inflammation-driven hepcidin elevation traps iron in macrophages and enterocytes, causing functional iron deficiency despite adequate or elevated total body iron stores. This is common in autoimmune diseases, chronic infections, and cancer. Anti-hepcidin therapies (including anti-hepcidin antibodies and hepcidin-binding peptides) are in development.

Hereditary Hemochromatosis

Genetic mutations that reduce hepcidin production or activity cause excessive iron absorption and tissue iron overload. The most common form involves mutations in the HFE gene. Iron overload damages the liver, heart, pancreas (causing diabetes), and joints.

Hepcidin-Targeted Therapeutics

The recognition of hepcidin as the master iron regulator has opened therapeutic avenues:

• Hepcidin mimetics — Synthetic minihepcidins are being developed for iron overload conditions.
• Anti-hepcidin agents — Antibodies and aptamers targeting hepcidin are being investigated for anemia of chronic disease.

Iron and Performance

Iron status directly affects exercise capacity, cognitive function, and recovery — parameters that many peptide protocol users are optimizing. Suboptimal iron status (even without frank anemia) can impair:

• Oxygen delivery to tissues (reduced hemoglobin)
• Mitochondrial function (iron-containing ETC complexes)
• Immune function (white blood cell activity)
• Thyroid hormone synthesis (iron-dependent thyroid peroxidase)

Monitoring ferritin, serum iron, transferrin saturation, and complete blood count is recommended as part of comprehensive blood work monitoring alongside peptide protocols.

See Also

• Red Blood Cell Production — Where most body iron resides
• Hepatic Detoxification — The liver as iron storage organ
• Blood Work Monitoring — Tracking iron status in peptide protocols
• Cytokine — Inflammatory mediators that regulate hepcidin
• Biomarker — Ferritin and transferrin saturation as iron markers